Atea Pharmaceuticals Appoints Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development
February 10, 2022 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for...
Atea Pharmaceuticals to Present at 11th Annual SVB Leerink Global Healthcare Conference
February 09, 2022 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct...
Atea Pharmaceuticals Announces Publication of Data Supporting Bemnifosbuvir’s (AT-527) Novel Mechanism of Action Against SARS-CoV-2 in Nature Communications
February 02, 2022 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that new data highlighting bemnifosbuvir...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atea Pharmaceuticals, Inc. - AVIR
February 01, 2022 18:39 ET
|
Pomerantz LLP
NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Atea Pharmaceuticals, Inc. (“Atea” or the “Company”) (NASDAQ: AVIR). Such investors are...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atea Pharmaceuticals, Inc. - AVIR
January 23, 2022 13:11 ET
|
Pomerantz LLP
NEW YORK, Jan. 23, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Atea Pharmaceuticals, Inc. (“Atea” or the “Company”) (NASDAQ: AVIR). Such investors are...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atea Pharmaceuticals, Inc. - AVIR
January 13, 2022 08:35 ET
|
Pomerantz LLP
NEW YORK, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Atea Pharmaceuticals, Inc. (“Atea” or the “Company”) (NASDAQ: AVIR). Such investors are...
Zev Asch Speaks About Disruptive Thinking for Small Business Owners
January 11, 2022 06:25 ET
|
Mission Matters Business Podcast
Beverly Hills , Jan. 11, 2022 (GLOBE NEWSWIRE) -- Zev Asch's mission and purpose are one and the same: to change the lives of business owners by helping them grow their companies and achieve a...
Atea Pharmaceuticals Highlights Strategic Priorities for 2022
January 07, 2022 07:00 ET
|
Atea Pharmaceuticals, Inc.
COVID-19: Planning global Phase 2 outpatient trial for bemnifosbuvir (AT-527) designed to support anticipated combination trials HCV: Obtained from Merck an exclusive worldwide license to ruzasvir...
Atea Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare Conference
January 03, 2022 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief...
Atea Pharmaceuticals Added to the Nasdaq Biotechnology Index
December 17, 2021 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the company has been added to the...